Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical tri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Jiang, Yafei, Wang, Gangyang, Mu, Haoran, Ma, Xiaojun, Wang, Zhuoying, Lv, Yu, Zhang, Tao, Xu, Jing, Wang, Jinzeng, Li, Yunqi, Han, Jing, Yang, Mengkai, Wang, Zongyi, Zeng, Ke, Jin, Xinmeng, Xue, Song, Yin, Mingzhu, Sun, Wei, Hua, Yingqi, Cai, Zhengdong
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8219214/
https://ncbi.nlm.nih.gov/pubmed/34168981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.642134
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars